Russell Greig, once president of GlaxoSmithKline subsidiary SR One, has taken the chairman position at drug developer BiomX, nine years after leaving the unit.
Russell Greig, previously president of SR One, the corporate venturing arm of UK-listed pharmaceutical firm GlaxoSmithKline (GSK), has joined Israel-based phage therapy developer BiomX.
Greig had spent about 30 years at GSK and was at one time president of its Pharmaceuticals International subsidiary, and was president of SR One between 2008 and 2010.
During his time at the unit, Greig served as chairman of biopharmaceutical companies Ablynx and Syntaxin – both SR One portfolio companies the corporate later exited, through…
